Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twelve-month study on immunogenicity, safety, and efficacy of Zarzio/Filgrastim HEXAL in severe chronic neutropenia
2011-001118-32Phase 3Terminated
- Sponsor
- Sandoz
- Start
- Apr 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of filgrastim in severe chronic neutropenia (SCN), congenital agranulocytosis (SCN), cyclic neutropenia (CN) and 2 more, sponsored by Sandoz. Primary endpoints: Incidence of anti-rhG-CSF antibodies and Incidence and severity of adverse events. Started Apr 2011; status: terminated.
02
Drugs
filgrastim
03
Conditions
severe chronic neutropenia (SCN)congenital agranulocytosis (SCN)cyclic neutropenia (CN)neutropeniaidiopathic neutropenia (CIN)
Beyond the preview
Go deeper on 2011-001118-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001118-32.